View Older Stories View More Recent Stories
-
Novo Nordisk's CagriSema shows blood pressure reduction in obesity trial
-
Novo CEO Says Bid For Metsera Is Higher Than Pfizer's Is Today
-
Novo Nordisk Is Said To Sweeten Bid For Obesity Startup Metsera - Bloomberg
-
Trump administration reaches GLP-1 drug pricing deals with Eli Lilly and Novo Nordisk - White House
-
Novo Nordisk commits additional $10B to U.S. investment - White House
-
Novo Nordisk (NVO) call put ratio 2.8 calls to 1 put with a focus on December 35 puts
-
Novo Nordisk (NVO) call put ratio 2 calls to 1 put amid price movement
-
Pfizer vows to continue Metsera legal fight after court denies restraining order
-
Novo Nordisk (NVO) PT Lowered to $50 at BMO Capital
-
Pfizer Preps Improved Offer In Metsera Bidding War - WSJ
-
Pfizer Denied Temporary Block On Novo Nordisk’s Metsera Bid - Bloomberg
-
Pfizer Drops Demand That Metsera Denounce Novo Bid: Metsera - Bloomberg
-
FTC Says Novo-Metsera Bid Raises Merger Filing Concerns - Bloomberg
-
Pfizer has removed conditions on sale of Arch Venture shares and Metsera public statements from its Metsera bid - Pfizer letter to court
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Novo Nordisk (NVO) Reports Q3 EPS of DKK4.50; offers outlook
-
Novo Nordisk earnings preview: Barclays and BofA weigh in
-
Trump admin talking to Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumpRx - WSJ
-
Novo Nordisk (NVO) call put ratio 3.1 calls to 1 put into quarter results
-
Pfizer (PFE) CEO: our bid for Metsera has taken into consideration that prices of GLP-1 will probably start going down - Conference Call
-
Lilly and Novo near White House deal on obesity drug prices - Endpoints News
-
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies - FT
-
Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into quarter results
-
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
-
Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
-
Metsera responds to Pfizer litigation amid competing acquisition bids
-
Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
-
Metsera responds to Pfizer litigation, will address claims in court
-
Pfizer sues Metsera directors and Novo Nordisk over merger breach
-
Pfizer gets early FTC clearance for Metsera acquisition
-
Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
Novo Nordisk makes $9 billion bid for Metsera amid Pfizer deal
-
Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
-
Novo Nordisk submits $6.5 billion offer for Metsera
-
Jefferies Assumes Novo Nordisk (NOVOB:DC) (NVO) at Underperform
-
Novo Nordisk (NVO) to hold EGM, Chair Helge Lund will not stand for reelection
-
Novo Nordisk calls extraordinary meeting to elect new board members
-
Novo Nordisk (NVO) call put ratio 1.2 calls to 1 put
-
After-hours movers: CSX Corp, Interactive Brokers, Novo Nordisk, Lilly
-
Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
-
Novo Nordisk (NVO): FDA approves Wegovy's supplemental NDA as amended for labeling with minor editorial revisions
-
Novo Nordisk (NVO) to announce layoffs in the U.S. - Reuters
-
Novo Nordisk (NVO) PT Raised to $55 at BMO Capital
-
Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion
-
Novo Nordisk (NVO) call put ratio 3.8 calls to 1 put with a focus on a spreader of December 60 and 85 calls
-
Goldman Sachs Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
